Entry Detail



General Information

Database ID:exR0080584
RNA Name:RPL22
RNA Type:mRNA
Chromosome:chr1
Starnd:-
Coordinate:
Start Site(bp):6185020End Site(bp):6209389
External Links:ENSG00000116251



Disease Information

Disease Name:Fragile X Syndrome
Disease Category:Congenital, Hereditary, and Neonatal Diseases and Abnormalities
MeSH ID:D005600
Type:Diseases Category/Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Alias:Fragile X Syndromes//Syndrome, Fragile X//Syndromes, Fragile X//Marker X Syndrome//Marker X Syndromes//Syndrome, Marker X//Syndromes, Marker X//Mental Retardation, X-Linked, Associated With Marxq28//X-Linked Mental Retardation and Macroorchidism//X Linked Mental Retardation and Macroorchidism//Fragile X Mental Retardation Syndrome//Martin-Bell Syndrome//Martin Bell Syndrome//Syndrome, Martin-Bell//Fra(X) Syndrome//FRAXE Syndrome//FRAXE Syndromes//Syndrome, FRAXE//Syndromes, FRAXE//Mental Retardation, X-Linked, Associated With Fragile Site Fraxe//Fragile X-F Mental Retardation Syndrome//Mar (X) Syndrome//FRAXA Syndrome//FRAXA Syndromes//Syndrome, FRAXA//Syndromes, FRAXA



Expression Detail

GEO ID:GSE83556
Description:Global transcriptome dysregulation in second trimester fetuses with FMR1 expansions
Experimental Design:Disease vs Control
Case Disease Type:Fragile X Syndrome
Case Disease SubType:NA
Case Sample:Fragile X Syndrome
Control Sample:Normal
Number of Case:22
Number of Control:18
Number of Samples:40





Regulatory Relationship

mRNA targets:
Gene SymbolChromosomeStart Site(bp)End Site(bp)Strand
ABTB2
chr11
34150987
34358010
-
AC007192.1
chr19
18153158
18178117
+
AC011462.1
chr19
41350853
41425001
+
AC015813.2
chr17
57989038
58007246
-
AC067968.1
chr19
44025354
44087318
+
AC092073.1
chr19
34396315
34409364
+
ACAT1
chr11
108116695
108147603
+
ACTG1
chr17
81509971
81523847
-
ACTR2
chr2
65227753
65271253
+
ADAR
chr1
154582057
154628013
-
ADIPOR1
chr1
202940826
202958572
-
AGO1
chr1
35869808
35930532
+
AHCY
chr20
34280268
34311802
-
AHCYL1
chr1
109984765
110023742
+
AHCYL2
chr7
129225023
129430211
+
AICDA
chr12
8602170
8612867
-
AK4
chr1
65147549
65232145
+
AKAP1
chr17
57085092
57121346
+
AKAP11
chr13
42272152
42323261
+
AKAP13
chr15
85380571
85749358
+
AL049779.1
chr14
67659820
67690367
-
AL136454.1
chr1
192716132
192716653
+
AL139300.1
chr14
103562962
103685924
+
AL365205.1
chr6
41780349
41790141
+
ALDOA
chr16
30064164
30070457
+
miRNA targets:NA
circRNA targets:NA
lncRNA targets:
lncRNA SymbolChromosomeStart Site(bp)End Site(bp)Strand
AC132217.1
chr11
2129121
2129964
-
AD000090.1
chr19
35557956
35581954
+
AL031847.1
chr1
6204840
6205780
-
Display:



Experiment Detail

GEO ID:GSE83556
Sample Source:Amniotic Fluid
Source Fraction:Supernatant
Platform:GPL570
Method:Microarray
Num of detected RNA Type:1
Num of detected RNAs of this Type:17063
Sample treatment protocol:RNA was extracted from 5-15 mL amniotic fluid supernatant (centrifugation at 350g, 4C, 10, min).
RNA Extract protocol:All samples were processed using the Qiagen Circulating Nucleic Acid kit with an on-column DNase digestion step to remove genomic DNA. The RNA was then purified and concentrated with the RNeasy MinElute Clean up kit and eluted in RNasefree water.
RNA library preparation protocol:RNA was converted to cDNA and amplified using the Ovation Pico WTA kit V2 and then purified with the QIAquick PCR Purification kit. Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA)Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA).



Reference

PMID:NA
Title:NA
Author:NA
Journal:NA
Description:NA